Investing.com - Regeneron Pharma (NASDAQ: REGN) reported fourth quarter EPS of $11.86, $1.09 better than the analyst estimate of $10.77. Revenue for the quarter came in at $3.43B versus the consensus estimate of $3.3B.
Regeneron Pharma's stock price closed at $957.78. It is up 17.25% in the last 3 months and up 22.30% in the last 12 months.
Regeneron Pharma saw 6 positive EPS revisions and 13 negative EPS revisions in the last 90 days. See Regeneron Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Regeneron Pharma's Financial Health score is "great performance".
Check out Regeneron Pharma's recent earnings performance, and Regeneron Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar